Distribution of trimethoprim and sulfametopyrazine in the female reproductive tract.
A combination of trimethoprim (TMP) 250 mg and sulfametopyrazine (SMP) 200 mg (dose ratio 5:4) in capsules was administered to ten patients undergoing hysterectomy for uterine leiomyoma. Each patient received a total of 3 of these Kelfiprim capsules: 2 capsules in a single administration 36 hours before surgery and 1 capsule 24 hours later. TMP and SMP concentrations were analyzed in plasma and also in the ovary, Fallopian tube and uterus, removed during surgery. The results indicated that in the reproductive organs of the female genital tract TMP reaches the same concentrations as in plasma. In contrast SMP is 3 to 3.5 times less concentrated in these tissues compared with plasma. At the TMP/SMP ratios obtained in these various organs synergism of the two compounds is reported to be particularly prominent for most bacterial strains. These findings indicate that this TMP-SMP combination may be useful in the treatment of female reproductive tract infections.
P C
PC
Preza
C
C
Moura
A
A
Leite Filho
V
V
Cavallari
F
F
Nüdemberg
F
F
Piaia
D000284:Administration, Oral; D000328:Adult; D004338:Drug Combinations / Q000008:administration & dosage / Q000378:metabolism; D005187:Fallopian Tubes / Q000032:analysis*; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007700:Kinetics; D008875:Middle Aged; D010053:Ovary / Q000032:analysis*; D013415:Sulfalene / Q000008:administration & dosage / Q000378:metabolism*; D013424:Sulfanilamides / Q000378:metabolism*; D013997:Time Factors; D014018:Tissue Distribution; D014295:Trimethoprim / Q000008:administration & dosage / Q000378:metabolism*; D014599:Uterus / Q000032:analysis*
D004338:Drug Combinations; D013424:Sulfanilamides; C026911:kelfiprim; D014295:Trimethoprim; D013415:Sulfalene